{{Drugbox
| IUPAC_name = 8-(Hexahydro-2,5-methanopentalen-3a(1''H'')-yl)-3,7-dihydro-1,3-dipropyl-1''H''-purine-2,6-dione
| image = Rolofylline.svg
| width = 220

<!--Clinical data-->
| tradename =  
| licence_US =  
| pregnancy_AU =  
| pregnancy_US =  
| pregnancy_category =  
| legal_AU =  
| legal_CA =  
| legal_UK =  
| legal_US = Rx-only
| legal_status =  
| routes_of_administration =

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =

<!--Identifiers-->
| IUPHAR_ligand = 5604
| CAS_number = 136199-02-5
| ATC_prefix = C03
| ATC_suffix = BD
| PubChem = 64627
| DrugBank =  
| ChemSpiderID = 58188
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 7805S5HIHX

<!--Chemical data-->
| C=20 | H=28 | N=4 | O=2 
| molecular_weight = 356.46 g/mol
}}
'''Rolofylline''' ('''KW-3902''') is an experimental [[diuretic]] which acts as a selective [[adenosine A1 receptor]] [[Antagonist (pharmacology)|antagonist]].<ref name="pmid17936154">{{cite journal |vauthors=Givertz MM, Massie BM, Fields TK, Pearson LL, Dittrich HC |title=The effects of KW-3902, an adenosine A1-receptor antagonist, on diuresis and renal function in patients with acute decompensated heart failure and renal impairment or diuretic resistance |journal=J. Am. Coll. Cardiol. |volume=50 |issue=16 |pages=1551–60 |date=October 2007 |pmid=17936154 |doi=10.1016/j.jacc.2007.07.019 |url=http://linkinghub.elsevier.com/retrieve/pii/S0735-1097(07)02324-8}}</ref><ref name="pmid18926433">{{cite journal | vauthors = Cotter G, Dittrich HC, Weatherley BD, Bloomfield DM, O'Connor CM, Metra M, Massie BM | title = The PROTECT pilot study: a randomized, placebo-controlled, dose-finding study of the adenosine A1 receptor antagonist rolofylline in patients with acute heart failure and renal impairment | journal = Journal of Cardiac Failure | volume = 14 | issue = 8 | pages = 631–40 |date=October 2008 | pmid = 18926433 | doi = 10.1016/j.cardfail.2008.08.010 | url =  }}</ref>  It was discovered at [[NovaCardia, Inc.]] which was purchased by [[Merck & Co., Inc.]] in 2007.

[[Drug development|Development]] of rolofylline was terminated on September 1, 2009, after the results of a large [[clinical trial]] (PROTECT) showed the drug to be no better than [[placebo]] for patients with acute heart failure. Participants given rolofylline did show some improvement in [[shortness of breath]], but the drug did not prevent kidney damage or have any [[statistical significance|significant]] effect on overall treatment success. Rolofylline was also associated with a higher [[incidence (epidemiology)|incidence]] of [[seizure]]s and [[stroke]].<ref>{{cite news |url=http://www.medscape.com/viewarticle/708267 |title=Rolofylline fails to PROTECT in acute heart failure |last=Hughes |first=Sue |date=September 1, 2009 |publisher=[[Medscape]] |accessdate=2009-09-02}}</ref>

==References==
{{Reflist|2}}

{{Adenosinergics}}

[[Category:Adenosine receptor antagonists]]
[[Category:Diuretics]]
[[Category:Xanthines]]


{{cardiovascular-drug-stub}}